Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
SSRX's Cash to Debt is ranked lower than
63% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. SSRX: No Debt )
SSRX' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: No Debt

Equity to Asset 0.90
SSRX's Equity to Asset is ranked lower than
77% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SSRX: 0.90 )
SSRX' s 10-Year Equity to Asset Range
Min: 0.16   Max: 0.97
Current: 0.9

0.16
0.97
Interest Coverage No Debt
SSRX's Interest Coverage is ranked lower than
140% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SSRX: No Debt )
SSRX' s 10-Year Interest Coverage Range
Min: 1   Max: 1000
Current: No Debt

1
1000
F-Score: 6
Z-Score: 15.31
M-Score: -3.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 19.20
SSRX's Operating margin (%) is ranked lower than
72% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. SSRX: 19.20 )
SSRX' s 10-Year Operating margin (%) Range
Min: 8   Max: 28.6
Current: 19.2

8
28.6
Net-margin (%) 15.30
SSRX's Net-margin (%) is ranked lower than
72% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. SSRX: 15.30 )
SSRX' s 10-Year Net-margin (%) Range
Min: 0.7   Max: 45.2
Current: 15.3

0.7
45.2
ROE (%) 7.50
SSRX's ROE (%) is ranked lower than
70% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. SSRX: 7.50 )
SSRX' s 10-Year ROE (%) Range
Min: 4.3   Max: 41.6
Current: 7.5

4.3
41.6
ROA (%) 7.00
SSRX's ROA (%) is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. SSRX: 7.00 )
SSRX' s 10-Year ROA (%) Range
Min: 4.1   Max: 21.4
Current: 7

4.1
21.4
ROC (Joel Greenblatt) (%) 11.40
SSRX's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. SSRX: 11.40 )
SSRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5   Max: 35.4
Current: 11.4

5
35.4
Revenue Growth (%) 19.00
SSRX's Revenue Growth (%) is ranked lower than
92% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. SSRX: 19.00 )
SSRX' s 10-Year Revenue Growth (%) Range
Min: 12.1   Max: 85.8
Current: 19

12.1
85.8
EBITDA Growth (%) 12.70
SSRX's EBITDA Growth (%) is ranked lower than
95% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. SSRX: 12.70 )
SSRX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 114.1
Current: 12.7

0
114.1
EPS Growth (%) 3.90
SSRX's EPS Growth (%) is ranked lower than
91% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. SSRX: 3.90 )
SSRX' s 10-Year EPS Growth (%) Range
Min: -1.4   Max: 280.6
Current: 3.9

-1.4
280.6
» SSRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

SSRX Guru Trades in Q3 2012

Jim Simons 404,200 sh (+5.32%)
Chuck Royce 161,280 sh (unchged)
» More
Q4 2012

SSRX Guru Trades in Q4 2012

Jim Simons 427,900 sh (+5.86%)
Chuck Royce 15,000 sh (-90.7%)
» More
Q1 2013

SSRX Guru Trades in Q1 2013

Jim Simons 689,308 sh (+61.09%)
Chuck Royce 15,000 sh (unchged)
» More
Q2 2013

SSRX Guru Trades in Q2 2013

Chuck Royce Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SSRX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2012-03-31 Sold Out 0.0036%$9.47 - $15.12 $ 13.0116%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.50
SSRX's P/E(ttm) is ranked higher than
72% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 22.50 )
SSRX' s 10-Year P/E(ttm) Range
Min: 11.32   Max: 35.5
Current: 22.5

11.32
35.5
P/B 1.80
SSRX's P/B is ranked higher than
52% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. SSRX: 1.80 )
SSRX' s 10-Year P/B Range
Min: 0.71   Max: 2.66
Current: 1.8

0.71
2.66
P/S 3.44
SSRX's P/S is ranked higher than
61% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. SSRX: 3.44 )
SSRX' s 10-Year P/S Range
Min: 2.62   Max: 11.91
Current: 3.44

2.62
11.91
PFCF 17.70
SSRX's PFCF is ranked higher than
63% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 17.70 )
SSRX' s 10-Year PFCF Range
Min: 11.41   Max: 100.14
Current: 17.7

11.41
100.14
EV-to-EBIT 12.20
SSRX's EV-to-EBIT is ranked higher than
51% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 12.20 )
SSRX' s 10-Year EV-to-EBIT Range
Min: 0.8   Max: 93.7
Current: 12.2

0.8
93.7
PEG 0.90
SSRX's PEG is ranked higher than
78% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 0.90 )
SSRX' s 10-Year PEG Range
Min: 0.8   Max: 2.05
Current: 0.9

0.8
2.05
Shiller P/E 25.30
SSRX's Shiller P/E is ranked higher than
64% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 25.30 )
SSRX' s 10-Year Shiller P/E Range
Min: 16.93   Max: 40.8
Current: 25.3

16.93
40.8
Current Ratio 16.38
SSRX's Current Ratio is ranked lower than
64% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. SSRX: 16.38 )
SSRX' s 10-Year Current Ratio Range
Min: 0   Max: 0
Current: 16.38

Quick Ratio 15.12
SSRX's Quick Ratio is ranked lower than
64% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. SSRX: 15.12 )
SSRX' s 10-Year Quick Ratio Range
Min: 0   Max: 0
Current: 15.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.40
SSRX's Price/Net Cash is ranked higher than
66% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. SSRX: 2.40 )
SSRX' s 10-Year Price/Net Cash Range
Min: 1.4   Max: 3.6
Current: 2.4

1.4
3.6
Price/Net Current Asset Value 10.50
SSRX's Price/Net Current Asset Value is ranked higher than
65% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. SSRX: 10.50 )
SSRX' s 10-Year Price/Net Current Asset Value Range
Min: 8.4   Max: 22.5
Current: 10.5

8.4
22.5
Price/Tangible Book 1.50
SSRX's Price/Tangible Book is ranked higher than
56% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. SSRX: 1.50 )
SSRX' s 10-Year Price/Tangible Book Range
Min: 1.1   Max: 2
Current: 1.5

1.1
2
Price/DCF (Projected) 1.20
SSRX's Price/DCF (Projected) is ranked higher than
79% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 1.20 )
SSRX' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 1.8
Current: 1.2

1.1
1.8
Price/Median PS Value 0.60
SSRX's Price/Median PS Value is ranked higher than
59% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. SSRX: 0.60 )
SSRX' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.4
Current: 0.6

0.7
2.4
Price/Peter Lynch Fair Value 0.80
SSRX's Price/Peter Lynch Fair Value is ranked higher than
84% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 0.80 )
SSRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 1.4
Current: 0.8

0.8
1.4
Price/Graham Number 0.40
SSRX's Price/Graham Number is ranked higher than
62% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 0.40 )
SSRX' s 10-Year Price/Graham Number Range
Min: 0.3   Max: 0.6
Current: 0.4

0.3
0.6
Earnings Yield (Greenblatt) 8.20
SSRX's Earnings Yield (Greenblatt) is ranked lower than
143% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SSRX: 8.20 )
SSRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 120.8
Current: 8.2

1.1
120.8
Forward Rate of Return (Yacktman) 21.79
SSRX's Forward Rate of Return (Yacktman) is ranked lower than
77% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. SSRX: 21.79 )
SSRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.7   Max: 22.7
Current: 21.79

2.7
22.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:YFK.Germany
» More Articles for NAS:SSRX

Headlines

Articles On GuruFocus.com
3SBio Inc. Announces Unaudited Second Quarter 2009 Results Aug 11 2009 

More From Other Websites
No related articles found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide